Research
Erasca presents early ERAS-0015 results in pancreatic and lung cancers
At 32 mg, ERAS-0015 shrank tumors in 11 of 25 pancreatic cancer patients and three of five lung cancer patients in early trial results reported by Medical Xpress.

Erasca presented early Phase I results for ERAS-0015, a pan-RAS cancer drug, from the AURORAS-1 trial. BioPharma Dive reported data from 122 people with pancreatic cancer whose disease had progressed after two or more treatment lines and who received daily doses of 16 to 32 mg. It said response rates exceeded those reported for Revolution Medicines’ Rasonque, but cautioned that cross-trial comparisons are error-prone and the drugs have not been compared head to head.
Medical Xpress reported findings from 148 trial participants, with results for 83 pancreatic cancer patients and 37 patients with non-small cell lung cancer. At 32 mg, tumors shrank in 11 of 25 pancreatic cancer patients (44%) and three of five lung cancer patients (60%). Twelve patients (9.8%) reported severe treatment-related side effects, and no side effects limited doses. The trial continues to enroll patients, and larger studies are needed to confirm safety and efficacy, Medical Xpress reported.


